| CNANew | +0.6%/+4.3%/+1.7% | 67.0 | 12.9B | Financial Services · Insurance - Property & Casualty | 🔵 Defensive(0.37) | Breakout | CNA is pressing the $48 resistance after a consolidation, with a breakout above $48 on strong volume potentially lifting the stock toward $50 and beyond the recent highs. Supports at $46 and $44 offer. | Open analysis |
| INCYNew | +1.1%/+2.8%/+2.4% | 65.0 | 19.3B | Healthcare · Biotechnology | 🟢 Low(0.86) | Breakout | INCY is at a critical juncture, attempting to break above the $100–$102 resistance with rising volume; a sustained breakout could target $108–$110 and rejoin the uptrend. The upcoming Q1 earnings data. | Open analysis |
| BNSNew | +1.2%/+2.8%/+1.2% | 65.0 | 89.3B | Financial Services · Banks - Diversified | 🟡 Elevated(1.19) | Breakout | BNS is breaking out from a tight range, with price action above consolidation and higher volume signaling momentum toward the next hurdle around $79.50. A decisive break above $79.50 could open furthe. | Open analysis |
| RYNew | +0.8%/+4.5%/+3.5% | 65.0 | 238.4B | Financial Services · Banks - Diversified | ⚪ Neutral(0.92) | Breakout | RY is testing the $175–$177 resistance after a prolonged uptrend; a confirmed breakout with volume could resume the move higher with targets above the current zone. Key supports at $163.50 and $161 pr. | Open analysis |
| RNR | +0.9%/+4.8%/+6.7% | 65.0 | 13.5B | Financial Services · Insurance - Reinsurance | 🔵 Defensive(0.24) | Breakout | RNR has broken out from consolidation, with immediate resistance around $310–$315 being tested; a sustained move above $315 on higher volume could extend gains, while $295 acts as near-term support. D. | Open analysis |
| MFCNew | +0.2%/+5.2%/+8.4% | 64.0 | 61.3B | Financial Services · Insurance - Life | 🟢 Low(0.73) | Breakout | MFC is testing the $37.75 resistance with an uptrend confirmed by higher volume, suggesting a potential breakout toward the next upside around $40–$42. Immediate supports at $35.20 and $33.40 provide . | Open analysis |
| GSK | +1.7%/+4.2%/+5.8% | 63.0 | 116.6B | Healthcare · Drug Manufacturers - General | 🔵 Defensive(0.35) | Breakout | GSK is attempting to break out of a 3-month consolidation around $58–$60, with a close above $60 on strong volume likely to push toward $63–$65 and potentially higher toward the $60 breakout zone. The. | Open analysis |
| SNNNew | +0.3%/+3.2%/+0.8% | 63.0 | 14.1B | Healthcare · Medical Devices | 🟢 Low(0.74) | Breakout | SNN is testing resistance near $33.32–$33.50 after a period of consolidation, with a breakout on volume potentially resuming the prior uptrend toward $35–$36 and beyond toward the $37–$38 area. Positi. | Open analysis |
| EXELNew | +2.7%/+3.1%/+8.8% | 62.0 | 12.2B | Healthcare · Biotechnology | 🔵 Defensive(0.42) | Breakout | Exelixis is breaking out of a multi-month consolidation, currently testing the $46 resistance on higher volume. A decisive close above $46 could carry the stock toward the mid-$50s where analysts have. | Open analysis |
| FTVNew | +1.4%/+7.7%/+7.1% | 61.0 | 19.1B | Technology · Scientific & Technical Instruments | ⚪ Neutral(1.00) | Breakout | FTV has confirmed a breakout from a multi‑month consolidation, with volume confirming the move and price testing the $60–$61.50 resistance. A sustained break above this zone could target the next hurd. | Open analysis |
| JAZZ | +1.1%/+5.2%/+6.9% | 60.0 | 12.2B | Healthcare · Biotechnology | 🔵 Defensive(0.23) | Breakout | Jazz is at a breakout attempt above the $200–$205 resistance, with rising volume confirming buying interest as it exits a multi-week consolidation. The stock remains in a longer-term uptrend from the . | Open analysis |
| GRMNNew | +1.5%/+8.0%/+9.1% | 60.0 | 49.4B | Technology · Scientific & Technical Instruments | ⚪ Neutral(0.97) | Breakout | GRMN is breaking out of a tight range around $260–$262, with a close above this zone on higher volume potentially resuming the long-term uptrend toward $270–$275. Support sits at $250–$252, offering r. | Open analysis |
| TXNNew | +2.9%/+9.5%/+8.2% | 60.0 | 195.7B | Technology · Semiconductors | ⚪ Neutral(0.99) | Breakout | TXN is breaking out of a consolidation, with rising volume confirming momentum as it approaches the $230 resistance; a sustained move beyond $230 could re‑test all‑time highs and target $240–$267 if t. | Open analysis |
| INTC | +4.7%/+28.5%/+28.6% | 60.0 | 309.9B | Technology · Semiconductors | 🟡 Elevated(1.35) | Breakout | INTC has broken out of a multi‑month consolidation with rising volume, pushing toward the $60 area and potentially higher toward $64–$67 if the breakout holds. The near-term resistance is around $60.1. | Open analysis |
| ASML | +1.9%/+6.5%/+4.5% | 57.0 | 568.8B | Technology · Semiconductor Equipment & Materials | 🟡 Elevated(1.38) | Breakout | ASML is consolidating near all-time highs, testing the $1453–$1460 area; a decisive breakout above this zone on higher volume could drive a fresh leg higher with targets beyond recent highs. The compa. | Open analysis |
| NOK | +1.2%/+15.5%/+20.9% | 93.0 | 53.3B | Technology · Communication Equipment | 🟢 Low(0.51) | Risk Adjusted Momentum | NOK is in a clear uptrend with supports at $8.50–$9 and $7.80–$8.20; resistance sits at $9.68–$9.80 and $10.00–$10.50. Catalysts include 5G deployments and cloud-RAN portfolio expansion; analysts are . | Open analysis |
| UI | +0.7%/+10.2%/+18.5% | 92.0 | 54.9B | Technology · Communication Equipment | 🟡 Elevated(1.32) | Risk Adjusted Momentum | UI exhibits a pronounced uptrend with supports around $850–$860 and $700–$720; immediate resistance sits near $900–$915, with a major psychological hurdle around $1000. Catalysts include record enterp. | Open analysis |
| DELL | -2.2%/+7.1%/+23.1% | 90.0 | 120.3B | Technology · Computer Hardware | ⚪ Neutral(0.95) | Risk Adjusted Momentum | DELL is in a strong uptrend with supports at $165–$170 and $145–$150, and near-term resistance around $185–$190 and a psychological $200 level. Catalysts include an Army contract win, AI-infrastructur. | Open analysis |
| MRVLNew | +4.8%/+12.4%/+32.6% | 90.0 | 104.9B | Technology · Semiconductors | 🔴 High(1.82) | Risk Adjusted Momentum | MRVL is in a healthy uptrend with support at $110 and a deeper base at $95; resistance sits near $125. Catalysts include AI/data-center demand and rising earnings/targets from analysts; price has brok. | Open analysis |
| CIEN | -1.3%/+17.3%/+43.4% | 89.0 | 68.9B | Technology · Communication Equipment | ⚪ Neutral(1.02) | Risk Adjusted Momentum | CIEN owns a powerful uptrend, with strong support near $450 and $410 and resistance at $513 and toward $550–$575; the stock trades at a high forward valuation but is supported by robust data-center/5G. | Open analysis |
| RPRX | +0.8%/-0.4%/+3.4% | 79.0 | 27.9B | Healthcare · Biotechnology | 🔵 Defensive(0.39) | Risk Adjusted Momentum | RPRX displays a strong uptrend, with current price near $48.30 and resistance at $48.50–$49 and $50–$52; supports at $46–$47 and $42–$44 define favorable risk zones. Catalysts include major funding de. | Open analysis |
| TW | -0.7%/+0.6%/+4.9% | 78.0 | 27.3B | Financial Services · Capital Markets | 🟢 Low(0.78) | Risk Adjusted Momentum | TW shows solid upside momentum with support at $115–$117 and a major floor near $100–$105; resistance sits at $125–$127 and $145–$150 as a long-term target. Catalysts include record trading volumes in. | Open analysis |
| MRK | -0.4%/+1.5%/+6.3% | 75.0 | 303.3B | Healthcare · Drug Manufacturers - General | 🔵 Defensive(0.28) | Risk Adjusted Momentum | MRK is in a solid uptrend, with immediate resistance around $125 and substantial upside toward all-time highs in the $150s; support sits around $115–$117. Catalysts include KEYTRUDA European approval . | Open analysis |
| TAK | -1.1%/-1.7%/+1.9% | 73.0 | 58.3B | Healthcare · Drug Manufacturers - Specialty & Generic | 🔵 Defensive(0.13) | Risk Adjusted Momentum | TAK is in a sustained uptrend with resistance near $18.80–$19.20 and a current price around $18.46; a decisive break above $19 could accelerate toward the next upside levels. Catalysts include positiv. | Open analysis |
| CBOENew | -0.7%/+5.2%/+3.8% | 72.0 | 30.9B | Financial Services · Financial Data & Stock Exchanges | 🔵 Defensive(0.37) | Risk Adjusted Momentum | CBOE is in an extended uptrend with support near $280–$285 and $265–$270, and resistance around $300–$305 and up toward all-time highs near $315–$320. Catalysts include Q4 earnings beat and product/ma. | Open analysis |
| CBNew | +0.1%/+1.8%/+3.5% | 69.0 | 130.2B | Financial Services · Insurance - Property & Casualty | 🟢 Low(0.50) | Risk Adjusted Momentum | CB sits in a persistent uptrend with immediate support near $330–$331.5 and a broader base at $310–$315; resistance sits around $335–$337 and the $340–$345 area with a longer-term target near $350. Ca. | Open analysis |
| SHG | +0.3%/+6.6%/+9.9% | 68.0 | 33.2B | Financial Services · Banks - Regional | 🟢 Low(0.73) | Risk Adjusted Momentum | SHG is in a strong uptrend with resistance around $70–$72.50 and support around $59–$61 and $52.50–$55. Catalysts include AI-driven efficiency, global expansion into markets like Vietnam, and ongoing . | Open analysis |
| EXASNew | +0.0%/+1.0%/+1.5% | 66.0 | 20.0B | Healthcare · Diagnostics & Research | 🟡 Elevated(1.44) | Risk Adjusted Momentum | EXAS shows a long-term bullish weekly trend with price above prior parabolic upmove. Immediate resistance sits near $104.91, with the 50-day moving average around $103.10 providing dynamic support; a . | Open analysis |
| UTHR | -1.2%/+0.8%/+5.5% | 66.0 | 25.2B | Healthcare · Drug Manufacturers - Specialty & Generic | 🟢 Low(0.75) | Risk Adjusted Momentum | UTHR is in an uptrend with new highs around the mid-$570s; near-term resistance sits around $580–$585 and a break above could open toward the $600s. Catalysts include positive regulatory momentum from. | Open analysis |
| ITUBNew | +2.2%/+6.2%/+7.6% | 66.0 | 99.3B | Financial Services · Banks - Regional | 🔵 Defensive(0.27) | Risk Adjusted Momentum | ITUB shows a long-running uptrend with key near-term resistance at $9.50 and support at $8.30 and $7.90. Catalysts include potential Citibank Brazil acquisition and steadily improving earnings estimat. | Open analysis |
